Pfizer Appoints New Chief Scientific Officer and President of R&D
Pfizer Inc. (NYSE: PFE) has announced the appointment of Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development, effective January 1, 2025. Dr.…
EU Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A/B in Adults and Adolescents
Pfizer Inc. (NYSE: PFE) has received marketing authorization from the European Commission (EC) for HYMPAVZI™ (marstacimab) for the routine prevention of bleeding episodes in patients aged 12 years and older,…
Tasfygo® Tablets 35mg Launched in Japan for FGFR2-Positive Biliary Tract Cancer
Eisai Co., Ltd. has announced the launch of TASFYGO® Tablets 35mg (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer harboring FGFR2 gene…
Bio-Techne Signs Distribution Agreement with Leader Life Sciences
Bio-Techne Corporation (NASDAQ: TECH), a leading global provider of innovative tools and bioactive reagents for research and clinical diagnostics, has announced a strategic partnership with Leader Life Sciences. Under this…
Improving Access to Pediatric Medicines on World Children’s Day
On World Children’s Day, the Global Accelerator for Paediatric Formulations Network (GAP-f) highlighted the urgent need for better access to essential medicines for children, particularly in low-resource settings. Despite their…
Local Climate Action, Global Health Benefits
On Wednesday, November 20, the UN Climate Conference (COP29) in Baku, Azerbaijan, spotlighted urbanization and transportation as critical areas for climate action. The day emphasized the pivotal role of cities…
Jazz Pharma Gains FDA Approval for Ziihera® to Treat Advanced HER2+ Biliary Tract Cancer
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL injection. This intravenous treatment is for adults with previously…
CVS Health® Becomes First Healthcare Company to Earn URAC Health Equity Accreditation
CVS Health is the first healthcare company to receive Health Equity accreditation from URAC, recognizing the work done through CVS Caremark and CVS Specialty. URAC sets high standards in healthcare…
Novartis Tops 2024 Access to Medicine Index
Novartis has secured the top spot in the 2024 Access to Medicine Index (ATMI), highlighting the company’s leadership in enhancing global access to medicines. The Access to Medicine Index, published…
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial, which assessed the noninferiority of subcutaneous pembrolizumab,…
Bayer Expands Cardiovascular Portfolio with Cytokinetics Aficamten in Japan
Bayer and Cytokinetics, Inc. (Nasdaq: CYTK) have announced a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan. Aficamten is a cardiac myosin inhibitor being…
BeiGene Announces Settlement with Generic Filer of BRUKINSA
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., has announced a settlement agreement with MSN Pharmaceuticals,…